Publicaciones en colaboración con investigadoras/es de Hospital de Cruces (12)

2023

  1. Using the Synergy between HPLC-MS and MALDI-MS Imaging to Explore the Lipidomics of Clear Cell Renal Cell Carcinoma

    Analytical Chemistry, Vol. 95, Núm. 4, pp. 2285-2293

2021

  1. Clinical implications of (Pro)renin receptor (prr) expression in renal tumours

    Diagnostics, Vol. 11, Núm. 2

  2. Soluble pd-l1 is an independent prognostic factor in clear cell renal cell carcinoma

    Cancers, Vol. 13, Núm. 4, pp. 1-17

2020

  1. The urinary transcriptome as a source of biomarkers for prostate cancer

    Cancers, Vol. 12, Núm. 2

2019

  1. Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting

    Actas Urologicas Espanolas, Vol. 43, Núm. 7, pp. 364-370

2017

  1. Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients

    PLoS ONE, Vol. 12, Núm. 8

2015

  1. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013

    European Urology, Vol. 68, Núm. 2, pp. 256-262

  2. Sequential combination of mitomycin C plus bacillus calmette-guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: Final outcome of CUETO 93009, a randomized prospective trial

    European Urology, Vol. 67, Núm. 3, pp. 508-516

2012

  1. The impact of peptidase activity on clear cell renal cell carcinoma survival

    American Journal of Physiology - Renal Physiology, Vol. 303, Núm. 12

2011

  1. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: External validation of the EORTC risk tables

    European Urology, Vol. 60, Núm. 3, pp. 423-430

2009

  1. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

    Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203

2008

  1. Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

    European Urology, Vol. 53, Núm. 5, pp. 992-1002